Hexarelin

Research-Grade

Hexarelin (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide growth-hormone-releasing peptide and the most potent GHSR-1a agonist in the classical GHRP family, producing greater peak GH release per dose than GHRP-2, GHRP-6, or ipamorelin. Like other GHRPs, it triggers GH secretion from anterior pituitary somatotrophs through the phospholipase-C/IP3/calcium signaling cascade. However, hexarelin's distinguishing pharmacological feature is its significant activity at CD36 scavenger receptors in cardiac tissue — a property not shared by other GHRPs. This CD36 interaction has produced reproducible cardioprotective effects in preclinical ischemia-reperfusion models, reducing infarct size and improving post-ischemic cardiac function. Critically, this cardioprotection persists even in hypophysectomized animals (lacking a pituitary gland and therefore incapable of GH release), confirming that the cardiac benefit operates independently of the GH axis. This dual receptor profile — GHSR-1a for GH release and CD36 for cardiac protection — makes hexarelin pharmacologically unique among growth-hormone secretagogues. Despite its potency advantages, hexarelin has significant practical limitations that explain its relatively limited off-label adoption compared to ipamorelin. First, it produces substantial elevations in both cortisol and prolactin at GH-effective doses, similar to GHRP-2 but more pronounced at higher dosing ranges. Second, and more problematic, hexarelin exhibits the most rapid tachyphylaxis (desensitization) of any GHRP — GH response diminishes noticeably within 4-8 weeks of continuous administration as the intense GHSR-1a activation accelerates receptor internalization and downregulation. This desensitization rate is faster than that observed with GHRP-2 or ipamorelin, effectively limiting hexarelin to short pulsed protocols rather than the sustained dosing preferred in most off-label GH optimization regimens. Hexarelin was investigated in several phase-2 clinical trials for cardiac and oncology indications that did not advance to commercialization. Its current relevance lies primarily in its unique cardioprotective mechanism and as a research tool for understanding GH secretagogue receptor pharmacology, while ipamorelin — despite weaker peak GH release — dominates chronic off-label use due to its clean selectivity and absence of tachyphylaxis.